Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 23 2023 - 10:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GSK plc (the 'Company')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms V Whyte
|
b)
|
Position/status
|
Company Secretary
|
c)
|
Initial
notification/amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature of
the transaction
|
Transfer of 9,110 Ordinary Shares between accounts for nil
consideration
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
9,110
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
Aggregated volume Price
|
|
e)
|
Date of the transaction
|
2023-02-20
|
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms V Whyte
|
b)
|
Position/status
|
Company Secretary
|
c)
|
Initial
notification/amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature of
the transaction
|
Transfer of 8,207 Ordinary Shares to spouse for nil
consideration
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
8,207
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
Aggregated volume Price
|
|
e)
|
Date of the transaction
|
2023-02-22
|
f)
|
Place
of the transaction
|
N/A
|
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr I Whyte
|
b)
|
Position/status
|
PCA of Ms V Whyte (Company Secretary)
|
c)
|
Initial
notification/amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature of
the transaction
|
Receipt of 8,207 Ordinary Shares from spouse for nil
consideration
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
8,207
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
Aggregated volume Price
|
|
e)
|
Date of the transaction
|
2023-02-22
|
f)
|
Place
of the transaction
|
N/A
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: February
23, 2023
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024